Strona główna・Stock List・Alkermes PLC

Alkermes PLC

Open

SectorHealthcare

49.33 -1.54

Buy Sell

Overview

Share price change

24h

Current

Min

49.05

Max

50.66

Key metrics
By Trading Economics
Income	-116M -66M
Sales	8.4M 393M
P/E Sector Avg	58.589 64.641
EPS	0.38
Profit margin	-16.92
Employees	2,050
EBITDA	-98M -22M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+16.01% upside

Dividends
By Acuity
Next Earnings	27 paź 2026

Market Stats
By TradingEconomics
Market Cap	3.1B 8.8B
Previous open	50.87
Previous close	49.33

News Sentiment

By Acuity

10%

90%

5 / 340 Ranking in Healthcare

Alkermes PLC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 sie 2026, 20:02 UTC

Alkermes shares are higher today, driven by significant gains in the overall market and major technology stocks, despite earlier session pullbacks.

31 lip 2026, 19:36 UTC

Alkermes Plc shares are lower today, impacted by declines in the Biotechnology sub-sector. The stock remains below its 20-day moving average.

30 lip 2026, 19:58 UTC

Alkermes Plc shares are higher during Thursday's session, reflecting a broader recovery in tech shares despite remaining below the 20-day moving average.

29 lip 2026, 20:03 UTC

News

Macro Event

Shares declining despite price target increases from JP Morgan, Baird.

28 lip 2026, 20:02 UTC

News

Event

Alkermes Plc shares are lower after reporting second-quarter earnings of 0 cents per share, below the consensus estimate of 29 cents.

24 lip 2026, 19:46 UTC

Alkermes Plc shares are lower today, pulling back after an early high. No specific news has been identified to explain the decline.

22 lip 2026, 19:36 UTC

Alkermes Plc shares are lower today, despite an earlier session high, amid rising crude oil prices and concerns over potential supply disruptions.

21 lip 2026, 18:46 UTC

Alkermes shares are higher today, supported by improved market sentiment and renewed interest in AI stocks. The asset is trading near its one-month range high.

20 lip 2026, 22:01 UTC

Alkermes Plc shares declined after-market, retracing from earlier peaks. The asset is currently below its 20-day moving average.

Peer Comparison

Price change

Alkermes PLC Forecast

Price Target

By TipRanks

16.01% upside

12 Months Forecast

Average 57.46 USD 16.01%

High 65 USD

Low 38 USD

Based on 13 Wall Street analysts offering 12 month price targets forAlkermes PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

13 ratings

Buy

Hold

Sell

Based on 13 analysts giving stock ratings to Alkermes PLC - Dist in the past 3 months.

Sentiment

By Acuity

5 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.